Close Menu

NEW YORK — The US Food and Drug Administration on Monday issued separate Emergency Use Authorizations for SARS-CoV-2 tests developed by MiraDx, Mammoth Biosciences, and BayCare Laboratories.

The MiraDx SARS-CoV-2 RT-PCR assay is designed to detect the N gene of the virus in upper respiratory specimens such as nasal swab specimens or nasal aspirates. It uses Hamilton's Microlab STAR automated liquid handling system for nucleic acid extraction and runs on Thermo Fisher Scientific's Applied Biosystems QuantStudio 6 Flex PCR instrument.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.